Search

everythinglearnresearchcommunity

for

Search:↓

The user shared progress pictures showing improved hair density after using topical Minoxidil for two years and topical Finasteride for one year, with occasional microneedling. They adjusted Finasteride concentration over time and are considering additional treatments like a hair transplant.

User started finasteride in Oct 2021 and experienced reduced shedding and side effects. Saw improvements in months 3-5, but worsening in months 11-13, and asks for advice on next steps.

The user started finasteride and minoxidil in December, increased the dosage after a few months, and noticed improvements around months 6 to 8 despite initial shedding. They experienced no side effects from finasteride but had to adjust minoxidil due to palpitations.

A 22-year-old is using 1mg finasteride daily for hair loss, noting some scalp thickening but still experiencing visible thinning. They are considering oral minoxidil due to concerns about topical application with cats at home, and others in the conversation share positive experiences with oral minoxidil, reporting no side effects and significant hair regrowth.

The conversation is about a user's 26-month hair loss treatment journey using finasteride, minoxidil foam, and microneedling, with gradual improvement in their hairline. The user applied treatments consistently and adjusted the frequency of microneedling based on feedback, noting that progress can feel slow compared to others.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

The user has been using finasteride for six months to address hair loss and is considering adding minoxidil to improve hair thickness. They are also using microneedling, peppermint oil, saw palmetto, biotin, and vitamin D supplements.

The user has been using chewable minoxidil and finasteride for 100 days, noticing some hair thickening and feeling more confident. The chewables contain 3mg minoxidil and 1.1mg finasteride.

The user is using 0.5 mg Dutasteride and 2.5 mg oral Minoxidil daily, along with weekly derma rolling, to address hair thinning. They have seen some improvement but are advised to wait at least 6 months for significant results.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

Spironolactone can remain effective for a long time in treating androgenetic alopecia, but it may not completely stop hair loss. Hair loss treatments like spironolactone, finasteride, and dutasteride slow down hair loss rather than cure it, and their effectiveness can vary based on individual response and the aggressiveness of the condition.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

Oral minoxidil may cause dry skin and dark eye bags but doesn't significantly age the skin. Topical minoxidil is toxic to cats, and some users prefer finasteride.

The user is experiencing worsening hair loss despite using finasteride and is advised to add minoxidil to their treatment. Concerns about side effects and the effectiveness of combining finasteride and minoxidil are discussed.

The user shared their experience with dutasteride for hair loss prevention, noting side effects like muscle weakness and brain fog, and observed increased testosterone levels. They recommend starting with a low dose and adjusting based on individual needs and blood work results.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

Topical finasteride is not known to be toxic to cats like minoxidil, but careful handling is advised to prevent ingestion or skin contact. OP seeks reassurance to convince their girlfriend of its safety around their cat.

Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The user is experiencing diffuse thinning after 10-11 months on oral finasteride and is concerned about whether this is a normal shedding phase. They have been using topical finasteride and minoxidil for over a year.

User tried oral dut 0.5mg, oral min 5mg, topical RU 80mg, and weekly microneedling at 1.5mm for hair loss. Others commented on the significant improvement and potential for future hair transplant.

The user has been using 0.25% topical finasteride and 5% minoxidil for 1.5 years with significant hair improvement and plans to start microneedling and possibly switch to oral finasteride for better long-term results. They are happy with the progress but seek more hair density and have not experienced any side effects.

Someone's two-month progress using oral minoxidil (2.5mg ED) to treat hair loss, which has resulted in thicker eyebrows and eyelashes but no scalp changes or shedding.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.